HYDRODYNAMICS OF MAGNETIC
DRUG TARGETING

P.A. Voltairas, D.I. Fotiadis, and L.K. Michalis

12 – 2001

Preprint, no 12 – 01 / 2001

Department of Computer Science
University of Ioannina
45110 Ioannina, Greece

Hydrodynamics of Magnetic Drug Targeting

P. A. Voltairas [a,1], D. I. Fotiadis [a] and L. K. Michalis [b]

[a] *Department of Computer Science, University of Ioannina, Ioannina 451 10, Greece*

[b] *Department of Cardiology, Medical School, University of Ioannina, Ioannina 451 10, Greece*

Abstract

Among the proposed techniques for delivering drugs to specific locations within the human body, magnetic drug targeting surpasses due to its non invasive character and its high targeting efficiency. Although the method has been proposed almost thirty years ago, the technical problems obstruct possible applications. It is the aim of the present work to classify them and propose satisfactory answers. A general phenomenological theory is developed and a model case is studied, which incorporates all the physical parameters of the problem.

Key words: Biomaterials; Biorheology; Ferrofluids; Magnetic Drug Targeting; Thrombosis.

1 Introduction

Magnetism is one of the major contributors in biological and biomedical research [1]. Among the many applications of magnetic carriers we mention some recent ones, such as the use of magnetic microbeads in DNA array biosensors [2], magnetic elastomers in otiatria as a biomimetic prosthetic tympanic membrane [3] and ferrofluid internal tamponade in retinal detachment surgery [4].

---

[1] Corresponding Author. Tel.: +30 651 98821; fax: +30 651 98889; e-mail: pvolter@cs.uoi.gr

Magnetite nanoparticles have been detected recently in the human hippocampus [5] and can shed some light to the process of iron biomineralization. Also the biological and neurophysiological effects of magnetic fields is the subject of a big controversy [6].

The concept of magnetic drug targeting is not new [7]. Efficient drug targeting is vital for the medical treatment of various diseases and among them of cardiovascular episodes, like stenosis and thrombosis. Ferrofluids, magnetoliposomes and magnetic micro and nanospheres are promising candidates, for delivering drugs to specific locations within the body, with high accuracy, minimum or no surgical intervention and maximum concentration. Their building blocks, the ferromagnetic particles, with the permanent magnetic polarization and the magnetophoretic mobility that they develop in an applied magnetic field, are responsible for their improved properties. The ternary phase structure of blood (white-red blood cells and plasma), as well as the plethora of particles that are present in the blood flow, makes hemodynamics an exceedingly complex research field. Visualization of complex flow patterns in the heart has been accomplished recently, through combined MRI and computational imaging techniques [8]. Moreover, the response of blood in magnetic fields in not yet completely known, though there are some indications for the diamagnetic, paramagnetic, or ferromagnetic character of its various constituents [9–11].

The thrombolytic properties of high magnetic fields is also an open field of investigation [12–14]. In arteriosclerosis episodes, like stenosis and thrombosis, what is important is to keep the thrombolytic drug, usually aspirin, in contact with the source of the problem, the endothelial cells, which are located along the inner wall of the blood vessel. Some *in-vitro* and *in-vivo* experiments have been performed in this direction [15–17]. Nevertheless, firm theoretical

2

foundation of magnetic drug targeting is still lacking.

Provided that the biocompatibility of magnetic particles will be accomplished, investigation of the conditions, for holding a ferrofluid drop on a blood vessel wall, is required. For that purpose, a self consistent phenomenological, ferrohydrodynamic model is proposed, to account for adhesion. The physical complexity, though it is not avoided, is kept to the minimum. Technical problems, concerning the design and the focusing of the strength of the externally applied nonuniform magnetic field, along the blood vessel wall, are stressed. We obtain an upper bound of the mean blood flow velocity as a function of the applied magnetic field, which permits quantitative estimation of the adherence condition. Comparison between the theoretically calculated and the experimentally observed blood velocity, for the carotid artery [18], confirm the presence of the upper bound, for given magnetic field strength, blood and magnetic drug viscosity and geometrical parameters of the model.

2 Ferrohydrodynamic Formulation

2.1 General Theory

In order to define conditions for adhesion of a magnetic fluid (ferrofluid) drug on a blood vessel wall, we encounter a highly complex situation, where we have to incorporate magnetostatic field effects on two phase (ferrofluid - blood) flow. Scrutiny requires taking also into account the effects of static magnetic fields on blood flow. The knowledge of the biological effects of static or dynamic electromagnetic fields is still in its infancy. The response of blood on static magnetic fields depends on a variety of factors like: oxygen content, pH, temperature gradients, etc. Thus, for example, plasma and leucocytes (like in most

3

biological tissues) are under normal conditions diamagnetic, while oxy- and deoxygenated erythrocytes are dia- and paramagnetic, respectively [9]. One might expect that since hemoglobin, the basic molecule that constitutes erythrocytes, contains an iron atom as a core, should be ferromagnetic, but it is its overall structure that results in the observed dia- or paramagnetic character. Thus conditions that will determine the strength of the external static magnetic field and the magnetic density of the ferrofluidic drug, for adherence, must be optimized in order to avoid possible side effects on the blood flow.

Although the exact rules that govern the physiology of blood circulation are still unknown, due to the diversity of the blood constituents and the complexity of the vascular system [19], we will assume that classical continuum hydrodynamical conservation laws are applicable. Thus according to the general theory of hydrodynamics, the blood and the magnetic drug flow are described by the conservation of momentum, or Navier-Stokes equations of fluid motion, in the absence of temperature gradients, augmented for the case of the magnetic drug with a magnetic body force term $\tau_{ij,j}^{M}$, [20]:

$$\tau_{ij,j} + \tau_{ij,j}^{M} + f_i = \rho \left(\frac{\partial u_i}{\partial t} + u_k u_{i,k} \right), \tag{1}$$

where

$$\tau_{ij} = -p\,\delta_{ij} + \eta\,(u_{i,j} + u_{j,i}), \tag{2}$$

$$\tau_{ij}^{M} = H_i\,B_j - \mu_o \left(\frac{H_k H_k}{2} + \int_0^H \frac{\partial(vM)}{\partial v} dH \right) \delta_{ij}, \tag{3}$$

$$B_i = \mu_o(H_i + M_i), \tag{4}$$

4

and by the conservation of mass:

$$\frac{\partial \rho}{\partial t} + \nabla \cdot (\rho \, \boldsymbol{u}) = 0. \tag{5}$$

Here, τ_{ij} is the stress tensor, τ_{ij}^{M} is the Maxwell stress tensor, f_i is the body force term, ρ is the density of the fluid, u_i is the velocity, p is the pressure, η is the viscosity, B_i is the magnetic induction, H_i is the magnetic field, M_i is the magnetization, $v = 1/\rho$ is the specific volume, μ_{o} is the magnetic permeability of vacuum and δ_{ij} is the Kronecker delta. $H_i = H_i' + H_i^{\mathrm{o}}$ is the total magnetic field due to external H_i^{o}, and internal H_i' origin. H_i' is usually known as the demagnetizing field produced by volume $\nabla \cdot \boldsymbol{M}$ or surface $\hat{\boldsymbol{n}} \cdot \boldsymbol{M}$ magnetic charges, where $\hat{\boldsymbol{n}}$ is the unit outward vector. The Einstein' s summation convention is adopted with $(\ )_{,i} \equiv \partial/\partial x_i$, and bold characters denote vector fields. In general it must be added to the Maxwell stress tensor (3) a term due to the non-collinearity of the magnetic field with the magnetization, proportional to $\boldsymbol{M} \times \boldsymbol{H}$. In the following we assume a magnetization collinear with the applied magnetic field ($M_i = \chi \, H_i$, χ is the magnetic susceptibility), thus such a term can be neglected. To the equations of fluid motion (1) the magnetostatic field equations must be added:

$$\nabla \cdot \boldsymbol{B} = 0, \tag{6}$$

$$\nabla \times \boldsymbol{H} = 0. \tag{7}$$

From hereafter the subscripts $(\ )_1$ and $(\ )_2$ will denote quantities of the magnetic drug and blood regions, respectively. The formulation of the initial boundary value problem (IBVP) (1,5-7) is completed with the appropriate initial and boundary conditions. The initial conditions for a pulsating fluid

5

flow are

$$u_i(t = t_0, \boldsymbol{r}) = \mathbf{v}_i(\boldsymbol{r}), \ i = 1, 2. \tag{8}$$

We have two boundary surfaces S_k, $k = 1, 2$, where $k = 1$ corresponds to magnetic drug - blood interface, and $k = 2$ to the blood vessel wall. When the magnetic drug is in contact with the blood vessel wall (also known as endothelium) we have to consider also another interface S_3 (Fig. 1(b)). On the interface S_1 the boundary conditions for the hydrodynamic problem (1) are

$$\hat{n} \cdot \boldsymbol{u}_1 = \hat{n} \cdot \boldsymbol{u}_2 = 0, \tag{9}$$

$$\hat{n} \times [\![\boldsymbol{u}]\!] = 0, \tag{10}$$

$$[\![\tau_{ij} + \tau_{ij}^M]\!] \, \hat{n}_i \, \hat{n}_j = \gamma \, n_{i,i}, \tag{11}$$

$$[\![\tau_{ij} + \tau_{ij}^M]\!] \, \hat{n}_i \, \hat{t}_j = 0, \tag{12}$$

where γ is the surface tension, $\hat{t}$ is tangential unit vector, and for the magnetic potential problem (5-6) are

$$\hat{n} \cdot [\![\boldsymbol{B}]\!] = 0, \tag{13}$$

$$\hat{n} \times [\![\boldsymbol{H}]\!] = 0. \tag{14}$$

The abbreviation $[\![A]\!] = A_2 - A_1$ is used in the boundary conditions (9-14). The BCs (9-12) correspond to the vanishing of the normal velocity components, to the continuity of the tangential velocity components, to the jump of the normal surface tractions and to the continuity of the tangential surface tractions, respectively, while the BCs (13-14) are the usual ones, for the magnetostatic

6

potential problem (6-7). The no slip conditions for the velocity field on the interfaces S_k, $k = 2, 3$ read:

$$\boldsymbol{u}_i = 0, \ i = 1, 2. \tag{15}$$

In a general pulsating flow the interfaces S_k, $k = 2, 3$ are not rigid but deform in an elastic or viscoelastic manner. Finally, the finiteness of the flow at the origin and at infinity requires:

$$\boldsymbol{u}_1(t, \boldsymbol{r} \rightarrow 0) = \boldsymbol{u}_0, \tag{16}$$

$$\boldsymbol{u}_2(t, \boldsymbol{r} \rightarrow \infty) = \boldsymbol{u}_\infty. \tag{17}$$

Similar conditions are necessary for the magnetic field $\boldsymbol{H}$ as well. The above developed IBVP has to be solved for the velocity field $\boldsymbol{u}(t, \boldsymbol{r})$, for given magnetic field configuration $\boldsymbol{H}(\boldsymbol{r})$. In the general case, the apparent difficulties are enormous, and so some special problems will be discussed below.

3   The Model

In order to appreciate on the difficulties that we encounter in the solution, we just mention that even in oversimplified cases where the hydrodynamic problem (1) is neglected and one faces the solution of the magnetostatic potential problem (6-7) and the free boundary condition (11), results are obtained only with properly designed finite element codes using supercomputers [21,22]. For that purpose a qualitative analysis will be presented, with emphasis on the responsible physical mechanisms for adherence, like the strength of the magnetic field and the magnetization of the ferrofluidic drug that overcomes the blood velocity. Well known analytical results will be combined to account for

7

the hydrodynamic drag exerted by the blood flow on the ferrofluidic drop and for the magnetophoretic driving force and its limitations. A more elaborated investigation, with the development of a numerical model, that will satisfy the full IBVP, described above, will be the subject of future investigations.

We assume that the magnetic drug constitutes a hemisphere like structure of radius R attached to the blood vessel wall, with the coordinate origin located on the center of the primitive circle on the equatorial plane of the hemispherical drop (Fig. 1(a-b)). Diffusion phenomena are neglected ($\rho_1 = \rho_2$). The blood vessel is considered to be an infinite, rectilinear, rigid, non-porous cylindrical tube, with smooth internal surface, of radius R_V. We will address the case $R_V \gg R$, in order for the equatorial plane of the hemispherical drop to coincide with the blood vessel wall. The ferrofluidic drug will originally be supplied through a catheter in the blood stream, thus it is more likely to have a prolate hemispheroidal like shape, but for computational convenience we investigate here a hemispherical like drop. The extension is straight forward for the prolate case and will be discussed in a future work. Moreover, adhesion effects, due to Van der Walls forces, possible lift effects on the drug - vessel wall interface and buoyancy forces will be neglected because of the strength of the magnetophoretic force. In order to simplify further the magnetic potential problem, we consider a diluted, incompressible ferrofluidic drug, with no temperature gradients. The first two of the above simplifications are justified, since we usually need water based drugs to avoid side effects. As far as the absence of temperature gradient effects is concerned, this is acceptable for local flow considerations. Then the third term of the Maxwell stress tensor of Eq. (3) will be omitted, the magnetization depends only on the external field ($\boldsymbol{H} \approx \boldsymbol{H}^\circ$), and the magnetic body force terms in the equation of fluid motion (1) vanishes. We will limit our discussion on the low Reynolds number

8

regime, where inertial effects are neglected. This is a legitimate approximation for capillaries and thin vessels, or for possible slow viscous flows in larger vessels. Then the equations of motion (1) and the equation of continuity (5), reduce to the Stokes flow for the velocity field $\boldsymbol{u}$:

$$\eta \nabla^2 \boldsymbol{u} = \nabla p, \tag{18}$$

$$\nabla \cdot \boldsymbol{u} = 0, \tag{19}$$

and the magnetostatic potential problem (6-7) is neglected. Similarly, due to the above assumptions the boundary conditions (11-12) are rewritten as:

$$[p_{vn} - p] + p_m + p_n = p_c, \tag{20}$$

$$[p_{vt}] = 0, \tag{21}$$

where

$$p_{vn} = 2\eta \, \hat{\boldsymbol{n}} \cdot \frac{\partial \boldsymbol{u}}{\partial \hat{n}}, \tag{22}$$

$$p_{vt} = \eta \left(\hat{\boldsymbol{t}} \cdot \frac{\partial \boldsymbol{u}}{\partial \hat{n}} + \hat{\boldsymbol{n}} \cdot \frac{\partial \boldsymbol{u}}{\partial \hat{t}} \right) \tag{23}$$

are the normal and tangential viscous pressures on the interface S_1, respectively, with $\partial/\partial\hat{n} \equiv \hat{\boldsymbol{n}} \cdot \nabla$, $\partial/\partial\hat{t} \equiv \hat{\boldsymbol{t}} \cdot \nabla$, and p_m, p_n and p_c have the usual notations as in [20]:

$$p_m = \mu_o \int_0^H M \, dH = \mu_o \int_0^H \chi H \, dH, \tag{24}$$

$$p_n = \frac{\mu_o M_n^2}{2} = \frac{\mu_o \chi^2 H_n^2}{2}, \tag{25}$$

$$p_c = \gamma \nabla \cdot \hat{\boldsymbol{n}} \tag{26}$$

9

with $H_n = \hat{n} \cdot H$ and $H_t = \hat{t} \cdot H$. In general, the constitutive law $M = \chi H$ might be nonlinear $(\chi = \chi(H))$, but in the following we will limit ourselves to a linear constitutive law $(\chi = const.)$. Notice the absence of magnetic pressure terms in Eq. (18). By considering for the moment axisymmetric solutions of the form

$$u = \nabla \times \left(\frac{\Psi(r, \theta)}{r \sin \theta} \hat{e}_\phi \right), \tag{27}$$

which fulfill condition Eq. (19), and by taking the curl of Eq. (18) this reduces to the following PDE for the stream function Ψ

$$\left[\frac{\partial^2}{\partial r} + \frac{\sin \theta}{r^2} \left(\frac{1}{\sin \theta} \frac{\partial}{\partial \theta} \right) \right]^2 \Psi = 0. \tag{28}$$

Following separation of variables of the form $\Psi = r^n \sin^k \theta$, and considering only the $k = 2$ mode, the permissible n's are $n = -1, 2, 3, 4$ thus:

$$\Psi = \left(\frac{C_1}{r} + C_2 r + C_3 r^2 + C_4 r^4 \right) \frac{\sin^2 \theta}{2}. \tag{29}$$

The constants in Eq. (29) are determined from the BCs (9-10, 12, 16-17) with

$$u_\infty = -u_0 = -u_0 \hat{e}_z, \quad (u_0 > 0), \tag{30}$$

and $\hat{e}_z = \cos \theta \hat{e}_r - \sin \theta \hat{e}_\theta$. Then the flows in regions (1) and (2) become:

$$u_1 = \lambda_3 u_0 \left[\left(1 - \left(\frac{r}{R} \right)^2 \right) \cos \theta \, \hat{e}_r - \left(1 - 2 \left(\frac{r}{R} \right)^2 \right) \sin \theta \, \hat{e}_\theta \right], \tag{31}$$

$$u_2 = u_0 \left\{ \left[2\lambda_1 \left(\frac{R}{r} \right) - 2\lambda_2 \left(\frac{R}{r} \right)^3 - 1 \right] \cos \theta \, \hat{e}_r - \right.$$
$$\left. - \left[\lambda_1 \left(\frac{R}{r} \right) + \lambda_2 \left(\frac{R}{r} \right)^3 - 1 \right] \sin \theta \, \hat{e}_\theta \right\}, \tag{32}$$

with

$$\lambda_1 = \frac{2\eta_2 + 3\eta_1}{4(\eta_1 + \eta_2)}, \quad \lambda_2 = \frac{\eta_1}{4(\eta_2 + \eta_1)}, \quad \lambda_3 = \frac{\eta_2}{2(\eta_1 + \eta_2)}. \tag{33}$$

Substitution of (31-32) into (18) and integration deduces the pressures

$$p_1 = 5\,\eta_1\lambda_3\,u_0\,r\,\frac{\cos\theta}{R^2}, \tag{34}$$

$$p_2 = 2\,\eta_2\lambda_1\,u_0\,R\,\frac{\cos\theta}{r^2}. \tag{35}$$

The solution (31-32) does not satisfy the no slip conditions (15). An efficient way to overcome this problem is to search for surfaces where two different flows coincide, and each one of the flows satisfy the appropriate boundary conditions in the region separated by the surface. This is permissible due to the linearity of the problem. Thus, for example, one such surface for the two flows $\boldsymbol{u}_{up}$ and $\boldsymbol{u}_{down}$ is the following:

$$(\boldsymbol{u}_{up} - \boldsymbol{u}_{down})^2 = 0. \tag{36}$$

In order to determine flows that satisfy the no slip conditions (15), we searched for asymmetric flows of the form (27) with $\Psi = \Psi(r, \theta, \phi)$ and no singularities inside the hemispherical drop, by the method of separation of variables. The only acceptable non-singular solution was the usual shear flow

$$\boldsymbol{u}_s = u_s\,x\hat{\boldsymbol{e}}_z. \tag{37}$$

Far away from the drop it is legitimate to assume that the flow is of the Poiseuille type

$$\boldsymbol{u}_p = u_p(r, \theta, \phi)\,(\cos\theta\,\hat{\boldsymbol{e}}_r - \sin\theta\hat{\boldsymbol{e}}_\theta), \tag{38}$$

11

with

$$u_p(r, \theta, \phi) = -u_0 \left[\left(\frac{r}{R} \right)^2 \sin^2 \theta - 2 \left(\frac{r}{R} \right) \sin \theta \cos \phi \right]. \qquad (39)$$

Looking for a surface of the form (36) inside the magnetic drop, with $\boldsymbol{u}_{up} = \boldsymbol{u}^{(1)}$ and $\boldsymbol{u}_{down} = \boldsymbol{u}_s$ we deduce that such a surface has a maximum at $x_m/R = (-\alpha \pm \sqrt{\alpha^2 + 8})/4$, $y = z = 0$, $\alpha = u_s/(\lambda_1 u_0)$, and intersects the equatorial plane $x = 0$, along a closed elliptic like curve with $z = \pm R$ and $y = \pm R/\sqrt{2} \approx \pm 0.7R$, which is not far from the primitive circle $r = R$. Notice that $0 \leq x_m/R \leq 1$ for $\alpha > 0$ and $\alpha \to 0$. Thus for the qualitative estimations presented here, the shear flow presented above is a sufficient approximation for the flow inside the drop and close to the blood vessel wall (equivalent results are obtained if we use instead of a shear a Poiseuille type flow). Following a similar procedure for the determination of surfaces that separate modified Poiseuille or shear flows outside the drop, we obtained acceptable results only for the space in front of the drop with respect to the direction of the blood velocity, but not behind. Nevertheless, despite the inconsistencies on the satisfaction of the no slip conditions (15) inside and outside the ferrofluidic drug drop, we will assume that the flow (31-32) is appropriate for our qualitative computations. In a more accurate calculation, it is expected that due to the no slip condition, the drag that experiences the magnetic drop will be a bit smaller from the one obtained from Eqs. (31-32).

4 The Adhesion Condition

Even if we will derive a flow that satisfies the BCs (15) we have also to fulfill the BC (20) on the free boundary S_1, that determines the type of deformation of the magnetic drop in the presence of the blood flow. Our primary concern

here is to estimate under what conditions the magnetic drop adheres to the blood vessel wall. In order to keep the mathematics simple without loosing the physical understanding, we might assume that the shape of the drop remains unaltered (hemispherical). Then we have to replace the capillary pressure (26) by the equivalent for the sphere

$$p_c = \frac{2\gamma}{R}. \tag{40}$$

With the substitution of Eq. (40) into (20) the later defines the stability boundary against decomposition into smaller drops, and thus it may be considered as a suitable adhesion condition. But even then we have to introduce an adapted inhomogeneous magnetic field, that will counteract to the blood flow, in order for the condition (20) to result in an expression for the mean blood velocity as a function of the maximum external field. For our problem geometry a legitimate form of the external magnetic field, would be in a first approximation that produced by a point source located outside the body at $x = -\delta$, $y = 0$, $z = \zeta$, $(\delta, \zeta > 0)$, (see Fig. 2(b)), of the form

$$\boldsymbol{H} = \frac{m\left(\boldsymbol{r} + \delta\hat{\boldsymbol{e}}_x - \zeta\hat{\boldsymbol{e}}_z\right)}{\left(r^2 + \delta^2 + 2\delta x - 2\zeta z\right)^{3/2}} \tag{41}$$

on the reference frame attached to the magnetic drop, with m the magnetic dipole moment. This is a typical Coulomb field. A dipole source would also be a sufficient approximation, but we adopt the form (41) since it approximates well conical magnetic spikes designs, of a biomedical apparatus. It has to be emphasized here that the non-uniformity of the applied magnetic field, which is vital for the magnetophoretic mobility of the ferrofluid drug, is higher only close to the magnetic pole. This is a major technical problem that has to be resolved, in order for the drug targeting to remain essentially non-invasive.

This limitation in bulk vessels is not present on surface ones. Semi-invasive techniques, like magnetic needles, provide always an alternative solution. The fact that the magnetic point source is oriented at an angle

$$\omega = \arcsin\left(\frac{\varsigma}{\delta}\right) \tag{42}$$

with respect to the x-axis of our coordinate system (see Fig. 2(b)) will be apparent from the following discussion. The boundary condition (11) or (20) can also be rewritten in vectorial form as:

$$[\boldsymbol{T}] = p_c \hat{\boldsymbol{n}}, \quad T_i = \left(\tau_{ij} + \tau_{ij}^M\right) n_j. \tag{43}$$

Substitution of (31-32) and (40-41) into (20) results in an expression that contains not similar azimuthal and polar components, which cannot be satisfied. In order to overcome this obstacle we might replace the local condition (20) by the more global one after integrating (20) over the surface area S_1, which written in dimensionless form, reads:

$$\frac{1}{B_m} = \frac{\chi}{4S_0} \iint\limits_{S_1} (h^2 + h_n^2) dS, \tag{44}$$

where

$$B_m = \frac{\mu_o H_0^2 R}{\gamma} \tag{45}$$

is the magnetic Bond number

$$h = \frac{H}{H_0}, \quad h_n = \frac{H_n}{H_0}, \quad H_0 = \frac{m}{\delta^2}, \quad S_0 = 2\pi R^2, \tag{46}$$

$$h = \frac{1}{\left[1 + \sin^2\omega + \left(\frac{R}{\delta}\right)^2 + 2\left(\frac{R}{\delta}\right)\sin\theta\cos\phi - 2\sin\omega\sin\theta\right]}, \tag{47}$$

14

$$h_n = \frac{\frac{R}{\delta} + \sin\theta\cos\phi + \sin\omega\cos\theta}{\left[1 + \sin^2\omega + \left(\frac{R}{\delta}\right)^2 + 2\left(\frac{R}{\delta}\right)\sin\theta\cos\phi - 2\sin\omega\sin\theta\right]^{3/2}}, \tag{48}$$

and $dS = R^2\sin\theta\,d\theta\,d\phi$. Due to the flow considered, the mean blood flow velocity u_0 does not enter into the adhesion condition (44), either directly through the viscous pressure (22-23), or indirectly through the hydrodynamic pressure (34-35). Placing the magnetic point source at $z = \zeta > 0\,(\omega \neq 0)$ (see Fig. 2(b)) results in a non-vanishing magnetic traction along the flow direction, that may balance the drag due to the blood flow. This traction balance can be expressed as an additional global condition, that results from the projection of Eq. (43) along the flow direction $\hat{e}_z$ and the integration over the surface of the magnetic drop S_1:

$$\iint\limits_{S_1} \left([\![T_z]\!] - p_c\,\hat{n}_z\right) dS = 0. \tag{49}$$

The above condition can be interpreted as a way to take into account the deformation of the magnetic drop due to the blood flow (see Fig. 2(a)), that it is not included in the proposed solution. Provided that we can express this angle ω as a function of the drop deformation, the model becomes also quantitative and further detailed calculations of the flow need not be performed. In dimensionless form Eq. (49) reads:

$$V_m = \frac{\chi}{4\beta\,S_0} \iint\limits_{S_1} \left[h^2 - (1+2\chi)h_n^2\right]\hat{n}_z\,dS, \tag{50}$$

where

$$V_m = \frac{\eta_1 u_0}{\mu_0 H_0^2 R}, \tag{51}$$

15

is the dimensionless velocity,

$$\beta = \gamma_v \left(\frac{\gamma_v - 1}{\gamma_v + 1} \right), \quad \gamma_v = \frac{\eta_2}{\eta_1}, \tag{52}$$

and $\hat{n}_z = \cos\theta$. Note that the capillary pressure does not enter the condition (50) as expected. Thus instead of one adhesion condition (44), we now have two Eqs. (44, 50) and the dependence of blood flow velocity on the applied magnetic field is parameterized as $B_m = B_m(R/\delta, \chi, \omega)$ and $V_m = V_m(R/\delta, \chi, \omega, \gamma_v)$. The obtained law $V_m = V_m(B_m)$ constitutes an upper bound to the correct one, since an additional constraint, Eq. (50), is introduced. Provided that a method can be devised that computes a lower bound close to the upper bound, the exact result may not need to be determined at all. Such a method, which will not be examined here, is to apply again the variational principle, that resulted to the field equations, after removing a positive term from the energy functional.

5 Results

The double integrals in Eqs. (44, 50) can in some cases be obtained in closed analytical form but since they do not have any irregular behavior they can be computed numerically with high accuracy. The β factor in Eq. (50), is susceptible of corrections, after computing a more accurate flow velocity field. Results are presented in Figs. 3(a-b) after eliminating ω, for varying viscosity ratio γ_v and magnetic susceptibility χ, respectively, and for two values of the ratio $R/\delta = 0, 0.2$. The limit $R \ll \delta$ (solid lines in Fig. 3) corresponds to a blood vessel far from the magnetic pole, like in the case of the thigh artery, with $R = 1\,mm$ and $\delta = 5\,cm$. The second case $R/\delta = 0.2$ with $\delta = 5\,mm$, (dashed lines in Fig. 3) corresponds to surface vessels, like veins. In Figs. 3(a-

16

b) the limiting values of the magnetic Bond number, where the blood velocity vanishes $V_m = 0$, are given by:

$$B_m = \frac{3}{\chi}, \tag{53}$$

for $R \ll \delta$. They correspond to $\omega = 0$, where the present approach fails to estimate the critical magnetic field required for adhesion of the magnetic drug. For a diluted ferrofluid with $\chi = 0.05$, in the limit of $R \ll \delta$ with $\omega = \pi/30$, and for $\gamma_v = 2/7$ we obtain from (44, 50) $B_m = 59.3453$, $-V_m = 0.0118$. These values correspond to a ferrofluid with viscosity $\eta_1 \approx 21 \times 10^{-3} N\, sec/m^2$, provided that the blood viscosity is $\eta_2 \approx 3\, \eta_{\text{plasma}} = 6 \times 10^{-3} N\, sec/m^2$, in the expected range $\eta_{\text{blood}} \approx (1.58 - 3.8) \times 10^{-3} N\, sec/m^2$ come across the literature [24,25], and the mean blood velocity is $-u_0 = V_m B_m\, \gamma/\eta_1 \approx 83.6925\, cm/sec$, which is a true upper bound to the calculated blood velocities for the carotid artery $(10 - 60)cm/sec$ [18]. The critical magnetic field for a drop of $R = 0.5\, mm$ is $H_0 = \sqrt{B_m\, \gamma/(\mu_o R)} \approx 109 kA/m$ or $0.14\, Tesla$.

6 Conclusions

The general theory for treating magnetic drug targeting, was developed. With minor corrections the theory can also be applied when the carrier is not a typical ferrofluid, but rather a lipid vessel (magnetoliposome). All necessary physical parameters like the strength and the orientation of the magnetic field, the magnetic composition of the drug, the blood composition and velocity are introduced in a model case. An upper bound to the critical magnetic field for magnetic drug capturing on blood vessel wall was derived. Provided that the orientation angle ω, of the applied magnetic field will be related to the deformation and the diffusion of the drug, the model might become also quan-

17

titative. The difficulties on the design of proper non-uniform driving magnetic fields were discussed. The flexibility of the model permits the treatment of, either bulk (arteries), or surface (veins) blood vessels. The biocompatibility of the magnetic micro and nanobeads is a major issue and is imminently related to the possibility of biomineralization. Iron biomineralization processes have been observed in a variety of living organisms. Thus, it is expected that magnetite beads are more biocompatible compared to the more toxic nickel or cobalt oxides. It has to be addressed here, that at the final stages of a clinical application of such a process the presence of the magnetic drug in the targeting area depends mainly to the extent of the stenosis. It is expected though that such a process will not take place for more than 10-15 minutes and more over a suction instrumentation might be present, so biocompatibility is preserved even for more toxic ferrofluidics. Finally, in a long perspective, issues like the diffusion and dispersion of the drop through the porous vessel wall and in the blood stream, the pulsating character of the blood flow, the elasticity of the blood vessel, or the phagocytosis of the magnetic drug (ferrofluid or magnetoliposome, in orgin) should also be investigated.

References

[1] W. Adrä and H. Nowak eds., 1998. *Magnetism in Medicine*, Wiley-VCH, New York.

[2] M. M. Miller et al, 2001. A DNA array sensor utilizing magnetic microbeads and magnetoelectronic detection. *J. Mag. Mag. Mat.* **225**, pp. 138-144.

[3] A. Kuznetsov et al, 2001. Application of magnetic devices in otiatria. *J. Mag. Mag. Mat.* **225**, pp. 202-208.

[4] P. A. Voltairas, D. I. Fotiadis and C. V. Massalas, 2001. *J. Mag. Mag. Mat.* **225**, pp. 248-255.

[5] P. P. Schultheiss-Grassi et al, 1999. TEM investigations of biogenic magnetite extracted from the human hippocampus. *Biochem. et Biophys. Acta* **1426**, pp. 212-216.

[6] A. Voustianiouk and H. Kaufmann, 2000. Magnetic fields and the central nervous system. *Clin. Neuropysiol.* **111**, pp. 1934-1935.

[7] K. Mosbach and U. Schröder, 1979. Preparation and application of magnetic polymers for targeting of drugs. *FEBS Lett.* **102**, pp. 112-116.

[8] P. J. Kilner et al, 2000. Asymmetric redirection of flow through the heart. *Nature* **404**, pp. 759-761.

[9] T. Higashi, N. Ashida, T. Takeuchi, 1997. Orientation of blood cells in static magnetic fields. *Physica B* **237-237**, pp. 616-620.

[10] M. Iwasaka, S. Ueno and H. Tsuda, 1994. Diamagnetic properties of fibrin and fibrinogen. *IEEE Trans. Mag.* **30**, pp. 4695-4697.

[11] Y. Haik, V. Pai and C. J. Chen, 2001. Apparent viscosity of human blood in a high static magnetic field. *J. Mag. Mag. Mat.* **225**, pp. 180-186.

[12] M. Iwasaka, S. Ueno and H. Tsuda, 1994. Effects of magnetic fields on fibrinolysis. *J. Appl. Phys.* **75**, pp. 7162-7164.

[13] M. Iwasaka, S. Ueno and H. Tsuda, 1996. Dissolution of thrombus under high gradient magnetic fields. *IEEE Trans. Mag.* **32**, pp. 5130-5132.

[14] M. Iwasaka, S. Ueno and H. Tsuda, 1998. Polymerization and dissolution of fibrin under homogeneous magnetic fields. *J. Appl. Phys.* **83**, pp. 6453-6455.

[15] A. N. Rusetski and E. K. Ruuge, 1990. Magnetic fluids as a possible drug carrier for thrombosis treatment. *J. Mag. Mag. Mat.* **85**, pp. 299-302.

[16] E. K. Ruuge and A. N. Rusetski, 1993. Magnetic fluids as drug carriers: targeted transport of drugs by a magnetic field. *J. Mag. Mag. Mat.* **122**, pp. 335-339.

[17] V. P. Torchilin, 2000. Drug targeting. *Eur. J. Pharm. Sci.* **11**(Suppl.), S81-S91.

[18] R. S. Perret and G. D. Sloop, 2000. Increased peak blood velocity in association with elevated blood pressure. *Ultrasound in Med. & Biol.* **26**, pp. 1387-1391.

[19] Y. C. Fung, 1997. *Biomechanics - Circulation* (2nd Edition), Springer Verlag, New York.

[20] R. E. Rosensweig, 1997. *Ferrohydrodynamics*, Dover Publications, New York.

[21] A. Boudouvis and L. E. Scriven, 1993. Sensitivity analysis of the hysteresis in deformation of ferrofluid drops. *J. Mag. Mag. Mat.* **122**, pp. 254-258.

[22] A. G. Papathanasiou and A. Boudouvis, 1999. Three dimensional magnetohydrostatic instabilities of rotating ferrofluid drops. *J. Mag. Mag. Mat.* **201**, pp. 290-292.

[23] L. D. Landau and E. M. Lifshitz, 1959. *Fluid Mechanics*, Pergamon Press, New York.

[24] F. C. Mokken et al, 1996. Differences in peripheral arterial and venous hemorheological parameters. *Ann. Hematol.* **73**, pp. 135-137.

[25] L. Dintenfass, 1968. Internal viscosity of the red cell and blood viscosity equation. *Nature* **219**, pp. 956-958.

Fig. 1. Model Geometry. (a) Cross-section along the $zx-$plane. (b) Coordinate system.

Fig. 2. The deformation of the magnetic drop (a) and its interpretation in the model (b).

Fig. 3. Magnetic Bond number B_m vs V_m, for (a) $\chi = 0.5$ and varying γ_v, (b) $\gamma_v = 0.5$ and varying χ. Solid lines correspond to $R/\delta = 0$ and dashed to $R/\delta = 0.2$.

(a)

(b)

Fig.1

Fig.2

(a)

$\chi = 0.5$
$R << \delta$
$R/\delta = 0.2$

$\gamma_v = 0.98$

0.95

0.9

0.8

0.7

B_m

$-V_m$

(b)

$\chi = 0.5$
$R << \delta$
$R/\delta = 0.2$

$\chi = 0.04$

0.06

0.08

0.1

B_m

$-V_m$

Fig.3